View Exam | PowerPak

1. The National Comprehensive Cancer Network (NCCN) defines febrile neutropenia based on:

A. An elevated temperature that lasts at least 24 hours plus a neutrophil count that is either below <500 neutrophils/µL projected to decline below this level over the next 48 hours B. An elevated temperature plus a neutrophil count that is either below <500 neutrophils/µL or projected to decline below this level over the next 48 hours C. An elevated temperature, a neutrophil count below <500 neutrophils/µL, and a documented infection D. An elevated temperature and a 25% reduction in neutrophil count from baseline.

2. Which of the following is a major contributor to the cost of febrile neutropenia?

A. Treatment with antibiotics B. Diagnostic tests to evaluate potential infection C. Hospitalization

3. The NCCN and the American Society of Clinical Oncology (ASCO) recommend the prophylactic use of granulocyte colony-stimulating factors (G-CSFs) in:

A. All patients receiving chemotherapy B. Patients with a 20% or higher risk of developing febrile neutropenia during chemotherapy C. Patients whose treatment plan includes both chemotherapy and radiotherapy

4. In addition to reducing the rates of febrile neutropenia, G-CSF use is associated with:

A. An increased use of antibiotics B. Reduced mortality C. More frequent fungal infections

5. Which agent is not approved by the Food and Drug Administration (FDA) for the prevention of neutropenia or reduction in the duration of neutropenia in patients receiving myelosuppressive therapy?

A. Filgrastim B. Pegfilgrastim C. Sargramostim D. Tbo-filgrastim

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The National Comprehensive Cancer Network (NCCN) defines febrile neutropenia based on:

2. Which of the following is a major contributor to the cost of febrile neutropenia?

3. The NCCN and the American Society of Clinical Oncology (ASCO) recommend the prophylactic use of granulocyte colony-stimulating factors (G-CSFs) in:

4. In addition to reducing the rates of febrile neutropenia, G-CSF use is associated with:

5. Which agent is not approved by the Food and Drug Administration (FDA) for the prevention of neutropenia or reduction in the duration of neutropenia in patients receiving myelosuppressive therapy?

« Return to Activity

Maintenance is scheduled for 08/28/2024 6:00 AM EST - 08/28/2024 5:00 PM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. The National Comprehensive Cancer Network (NCCN) defines febrile neutropenia based on:

2. Which of the following is a major contributor to the cost of febrile neutropenia?

3. The NCCN and the American Society of Clinical Oncology (ASCO) recommend the prophylactic use of granulocyte colony-stimulating factors (G-CSFs) in:

4. In addition to reducing the rates of febrile neutropenia, G-CSF use is associated with:

5. Which agent is not approved by the Food and Drug Administration (FDA) for the prevention of neutropenia or reduction in the duration of neutropenia in patients receiving myelosuppressive therapy?

« Return to Activity

Customers who Purchased
this Activity also Purchased